Literature DB >> 19954691

Aldosterone and diabetic kidney disease.

Young Sun Kang1, Dae Ryong Cha.   

Abstract

Aldosterone plays an important role in salt and water homeostasis and blood pressure control through the classical mineralocorticoid receptor. However, recent findings of the mineralocorticoid receptor in nonepithelial tissues suggest that aldosterone may have additional functions. Significant evidence now exists suggesting that aldosterone directly induces tissue injury. Systemic or local aldosterone has emerged as a multifunctional hormone exhibiting profibrotic and proinflammatory actions that extend beyond the classical hemodynamic effect. The incomplete blockade of the renin-angiotensin-aldosterone system by angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers has led to experimental and clinical efforts using aldosterone inhibition. Recently, these efforts have provided us with an expanded understanding of a new pathogenic role for aldosterone in diabetic vascular complications. This article focuses on the role of aldosterone in the pathogenesis of diabetic kidney disease and recent important clinical data supporting the inhibition of aldosterone in treating diabetic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19954691     DOI: 10.1007/s11892-009-0074-x

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  46 in total

1.  Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats.

Authors:  Natalia de las Heras; Marta Ruiz-Ortega; María Miana; Mónica Rupérez; David Sanz-Rosa; Paloma Aragoncillo; Sergio Mezzano; Victoria Cachofeiro; Jesús Egido; Vicente Lahera
Journal:  J Hypertens       Date:  2007-03       Impact factor: 4.844

Review 2.  Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade.

Authors:  Lucia Del Vecchio; Mirella Procaccio; Sara Viganò; Daniele Cusi
Journal:  Nat Clin Pract Nephrol       Date:  2007-01

3.  Plasma aldosterone concentration in the patient with diabetes mellitus.

Authors:  Norman K Hollenberg; Radomir Stevanovic; Anupam Agarwal; M Cecilia Lansang; Deborah A Price; Lori M B Laffel; Gordon H Williams; Naomi D L Fisher
Journal:  Kidney Int       Date:  2004-04       Impact factor: 10.612

4.  High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes.

Authors:  A Sato; J W Funder
Journal:  Endocrinology       Date:  1996-10       Impact factor: 4.736

5.  Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species.

Authors:  Mabel J van den Hoven; Femke Waanders; Angelique L Rops; Andrea B Kramer; Harry van Goor; Jo H Berden; Gerjan Navis; Johan van der Vlag
Journal:  Nephrol Dial Transplant       Date:  2009-05-09       Impact factor: 5.992

6.  Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.

Authors:  Yoshiyuki Furumatsu; Yasuyuki Nagasawa; Kodo Tomida; Satoshi Mikami; Tetsuya Kaneko; Noriyuki Okada; Yoshiharu Tsubakihara; Enyu Imai; Tatsuya Shoji
Journal:  Hypertens Res       Date:  2008-01       Impact factor: 3.872

7.  Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.

Authors:  Murray Epstein; Gordon H Williams; Myron Weinberger; Andrew Lewin; Scott Krause; Robin Mukherjee; Rajiv Patni; Bruce Beckerman
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-19       Impact factor: 8.237

8.  Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole.

Authors:  Shuji Arima; Kentaro Kohagura; Hong-Lan Xu; Akira Sugawara; Akira Uruno; Fumitoshi Satoh; Kazuhisa Takeuchi; Sadayoshi Ito
Journal:  Hypertension       Date:  2003-12-22       Impact factor: 10.190

9.  Aldosterone induces CTGF in mesangial cells by activation of the glucocorticoid receptor.

Authors:  Stefan Gauer; Verena Segitz; Margarete Goppelt-Struebe
Journal:  Nephrol Dial Transplant       Date:  2007-06-30       Impact factor: 5.992

10.  Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells.

Authors:  Wei Huang; Chen Xu; Kyoung W Kahng; Nancy A Noble; Wayne A Border; Yufeng Huang
Journal:  Am J Physiol Renal Physiol       Date:  2008-03-26
View more
  3 in total

1.  Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis.

Authors:  Xinrui Jiang; Zhengji Zhang; Chunlu Li; Shijin Zhang; Qiang Su; Siyun Yang; Xin Liu; Ying Hu; Xiaofeng Pu
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

2.  Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!

Authors:  Vajir Malek; Sachin V Suryavanshi; Nisha Sharma; Yogesh A Kulkarni; Shrikant R Mulay; Anil Bhanudas Gaikwad
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 3.  Molecular Mechanisms of Diabetic Kidney Disease.

Authors:  Jorge Rico-Fontalvo; Gustavo Aroca; Jose Cabrales; Rodrigo Daza-Arnedo; Tomas Yánez-Rodríguez; María Cristina Martínez-Ávila; Isabella Uparella-Gulfo; María Raad-Sarabia
Journal:  Int J Mol Sci       Date:  2022-08-04       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.